Cell Signaling Technology, Inc. Sustainability Profile
Cell Signaling Technology, Inc. (CST), headquartered in the United States, is a leading provider of innovative research tools in the life sciences industry. Founded in 1999, CST has established itself as a key player in the field of cell signalling, offering a comprehensive range of high-quality antibodies, assays, and reagents that support cutting-edge research in cancer, neuroscience, and immunology. With a commitment to scientific excellence, CST's products are distinguished by their specificity and reliability, making them essential for researchers worldwide. The company has achieved notable milestones, including numerous awards for product innovation and quality, solidifying its position as a trusted partner in the scientific community. Through its dedication to advancing cell signalling research, Cell Signaling Technology continues to empower scientists in their quest for discovery.
DitchCarbon Score
How does Cell Signaling Technology, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cell Signaling Technology, Inc.'s score of 46 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cell Signaling Technology, Inc.'s reported carbon emissions
In 2023, Cell Signaling Technology, Inc. reported total carbon emissions of approximately 8,000,000 kg CO2e, comprising 1,115,000 kg CO2e from Scope 1, 2,915,000 kg CO2e from Scope 2, and 4,030,000 kg CO2e from Scope 3 emissions. This reflects a slight decrease in Scope 1 and Scope 3 emissions compared to 2022, where total emissions were about 8,000,000 kg CO2e, with Scope 1 at 1,157,000 kg CO2e, Scope 2 at 2,910,000 kg CO2e, and Scope 3 at 4,067,000 kg CO2e. Cell Signaling Technology has committed to achieving net-zero emissions by 2029, making it the first life science member to set such a target. This commitment encompasses all scopes of emissions, indicating a comprehensive approach to climate action. The company is actively working towards this goal, although specific reduction percentages have not been disclosed. The emissions data is not cascaded from any parent organization, and all figures are directly reported by Cell Signaling Technology, Inc. This commitment to transparency and accountability in emissions reporting aligns with industry standards in the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 3,252,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,154,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 3,393,000 | 0,000,000 | 0,000,000 | 0,000,000 |
How Carbon Intensive is Cell Signaling Technology, Inc.'s Industry?
How Carbon Intensive is Cell Signaling Technology, Inc.'s Location?
Cell Signaling Technology, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cell Signaling Technology, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Cell Signaling Technology, Inc.'s sustainability data and climate commitments